Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RVX.TO
- Price
- 0.04
- Stock movement up
- +- (%)
- Company name
- Resverlogix Corp.
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 12.63M
- Ent value
- 102.76M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -25.00%
- 3 year return
- -53.92%
- 5 year return
- -45.43%
- 10 year return
- -29.62%
Last updated: 2025-04-09
DIVIDENDS
RVX.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 280.65M |
| EPS (TTM) | -0.03 |
| FCF per share (TTM) | -0.02 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -3.23M |
| Net income (TTM) | -8.10M |
| EPS (TTM) | -0.03 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 43.00K |
| Net receivables | 0.00 |
| Total current assets | 1.88M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 7.71M |
| Accounts payable | 16.28M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 24.82M |
| Total liabilities | 90.18M |
| Shareholder's equity | -82.47M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -2.89M |
| Capital expenditures (TTM) | 395.00K |
| Free cash flow (TTM) | -5.06M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -105.13% |
| Return on Invested Capital | 10.90% |
| Cash Return on Invested Capital | 6.80% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.04 |
| Daily high | 0.04 |
| Daily low | 0.04 |
| Daily Volume | 44K |
| All-time high | 25.78 |
| 1y analyst estimate | 7.70 |
| Beta | 0.82 |
| EPS (TTM) | -0.03 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 10 May 2025 |
Downside potential
Loading...
Downside potential data
| RVX.TO | S&P500 | |
| Current price drop from All-time high | -99.83% | -19.00% |
| Highest price drop | -99.84% | -56.47% |
| Date of highest drop | 3 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -78.23% | -11.07% |
| Avg time to new high | 62 days | 12 days |
| Max time to new high | 4544 days | 1805 days |
COMPANY DETAILS
Marketcap
12.63M
Marketcap category
Small-cap
Description
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company is headquartered in Calgary, Canada.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Numerous GLP-1 RA and SGLT2i presentations touted their clinical results, providing continued excitement for our BETonMACE program, which observed a non-prespecified 63% reduction in MACE and heart fa...
September 3, 2024
Calgary, Alberta--(Newsfile Corp. - July 31, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual & Special Meeting of Shareholders (the "Meeting") in Calga...
July 31, 2024
Calgary, Alberta--(Newsfile Corp. - July 16, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced it has entered into definitive transaction documents for the two-year exten...
July 16, 2024
Calgary, Alberta--(Newsfile Corp. - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") wi...
May 28, 2024
Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertib...
May 13, 2024